Korea Investment Partners

Raywatt is a startup focused on developing innovative medical devices for cardiovascular interventions. The company specializes in a health technology platform that utilizes laser-based imaging technology to enhance the diagnosis and treatment of cardiovascular diseases. Raywatt's offerings include optical coherence tomography (OCT)-based machine learning for fractional flow reserve (FFR) prediction, as well as catheter-based high-speed OCT imaging. These advanced imaging technologies provide healthcare professionals with high-speed and high-resolution tools to improve patient outcomes in the field of cardiology.

Healing Paper leverages information technology to enhance accessibility to medical services, reduce costs, and facilitate balanced communication between healthcare professionals and non-experts.

Gangnam Unni is in the field of beauty medical services, helping users choose a treatment and a plastic surgery hospital. The difficulty of navigating the process of seeking medical treatment and choosing a hospital continues to persist. Kangnam Unni recognizes the need for change and firmly believes that a combination of transparent medical information and an IT platform can foster a consumer-oriented medical service market. Their ultimate goal is to challenge negative perceptions surrounding plastic surgery and spearhead a significant transformation in the beauty and medical service industries. The Gangnam Unni team is dedicated to innovation, fueled by an unwavering desire to provide exceptional beauty and medical services. With the aim of assisting individuals in selecting a suitable hospital, they have amassed an impressive database of one million user reviews. Additionally, their efforts to promote transparency in medical information have garnered the support of 3,000 subscribers through Gangnam Sister. Furthermore, their mobile application has facilitated hospital consultations for a staggering 3.8 million individuals, resulting in 1.6 million successful cases. As the team continuously clarifies its mission and forges ahead with determination, its collective strength and resolve only grow stronger. Kangnam Unni remains committed to revolutionizing the healthcare industry, ensuring that individuals receive the highest quality of care and a positive experience throughout their medical journeys.

Selta Square is a company specializing in AI-driven drug monitoring solutions. It employs artificial intelligence technology to offer comprehensive drug monitoring services, allowing pharmacovigilance experts to minimize repetitive tasks and focus on critical evaluations.

MyHerb Healthcare proivdes a specialized analysis for nutritional supplements.

Raywatt is a startup focused on developing innovative medical devices for cardiovascular interventions. The company specializes in a health technology platform that utilizes laser-based imaging technology to enhance the diagnosis and treatment of cardiovascular diseases. Raywatt's offerings include optical coherence tomography (OCT)-based machine learning for fractional flow reserve (FFR) prediction, as well as catheter-based high-speed OCT imaging. These advanced imaging technologies provide healthcare professionals with high-speed and high-resolution tools to improve patient outcomes in the field of cardiology.

Pin Therapeutics is a biotechnology company developing therapeutic products that target disease-causing proteins for immune diseases, cancer, and aging-related conditions. It employs protein degradation systems to break down these proteins.

ALDAVER provides incredibly realistic personalized surgical training models using innovative biopolymer materials that closely resemble human tissues and 3D printing technology.

MicrobiotiX develops bacteriophage and microbiome-based therapeutics to combat multidrug-resistant infections and autoimmune diseases, and pursues therapeutic diagnostic technologies to enable microbiome-focused treatments. The company’s platform supports safe gastrointestinal microbiota transplant in a medical setting, formulates fecal microbiota transplant capsules for oral administration, and conducts research and development of bacteriophages, with the aim of delivering convenient, economical therapies that reduce infection risk. Through these approaches, MicrobiotiX seeks to advance microbiome and phage therapies for difficult-to-treat conditions, integrating diagnostics with therapeutics to streamline patient care.

Thorough Future specializes in integrating advanced technology into medical care. It focuses on enhancing diagnostic services' accuracy and efficiency for clinical medicine and providing personalized treatment recommendations, particularly for cancer patients.

Syntekabio, Inc. is a bioinformatics company based in Daejeon, South Korea, founded in 2009. The firm specializes in genome analysis and the integration of bio data, utilizing advanced algorithms to create personal genome maps that facilitate disease prevention and the development of customized medications. Syntekabio also offers a technology for collecting and integrating decrypted whole genome data, which is instrumental in analyzing diseases, including rare conditions. Their MAHA supercomputer significantly reduces data-processing costs and enhances genome-based diagnostics. The company focuses on gene-related research and technology development, leveraging a genome big data platform and artificial intelligence for drug development and genetic analysis.

PulseSight Therapeutics is an ophthalmology-focused biotechnology company developing treatments for severe retinal diseases. It advances non-viral gene therapies delivered through minimally invasive methods to address blindness associated with retinal conditions. In addition, the company develops therapeutic proteins aimed at treating both short- and long-term retinal disorders, including chronic non-infectious uveitis, degenerative diseases, retinal vascular diseases, and macular edema. These approaches seek to improve ocular bioavailability and tolerability while supporting adherence to treatment. By focusing on therapies that preserve and improve vision, PulseSight aims to provide physicians and ophthalmologists with options that address unmet clinical needs and improve patient quality of life.

DYNE Medical Group is a medical equipment manufacturer specializing in endoscopy devices and artificial intelligence solutions for urological surgery. The company focuses on developing innovative manufacturing technologies that incorporate reusable flexible endoscopes, utilizing a unique optimization design and ultra-precision processing. This advanced approach aims to enhance the effectiveness of endoscopic procedures, facilitating minimally invasive treatments for patients. Additionally, DYNE Medical Group is committed to providing AI-based cancer diagnostics, further supporting healthcare professionals in delivering improved patient care.

Brexogen is a biotechnology company focused on cell therapy research and development. It specializes in creating optimized parental cells for exosome production, aiming to treat incurable diseases through stem cell exosomes.

Thorough Future specializes in integrating advanced technology into medical care. It focuses on enhancing diagnostic services' accuracy and efficiency for clinical medicine and providing personalized treatment recommendations, particularly for cancer patients.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

S-Alpha Therapeutics Inc. is a digital therapeutics company based in Seoul, South Korea, established in 2019. It specializes in researching and developing health applications and platform technologies that leverage digital devices for the treatment of various diseases. The company’s product pipeline includes SAT-001, an application focused on ophthalmology for eye disease treatment; SAT-002, which addresses neurological conditions; SAT-003, designed for oncology to support cancer patients in their recovery; and SAT-008, aimed at public crises to address social issues. In addition to its health applications, S-Alpha Therapeutics also develops therapeutic devices, striving to provide innovative solutions for unmet medical needs across multiple therapeutic areas, including ophthalmology, neuropsychiatry, and cancer.

S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

S&E Bio is a biopharmaceutical company specializing in the development of cell therapies aimed at addressing neurological disorders. The company focuses on creating safe and effective treatments using stem cell-derived extracellular vesicles, particularly mesenchymal stem cell-derived therapeutics. S&E Bio targets a range of conditions, including acute stroke, moyamoya disease, chronic stroke, dementia, and cognitive disorders. Through its innovative approach to stem cell therapy, the company seeks to provide advanced treatment options for patients suffering from these incurable diseases, enhancing their quality of life and treatment outcomes.

Oncobix is a drug development company focused on creating innovative treatments for rare and incurable diseases that are difficult to address with current medical practices. The company has developed a novel compound, represented by a specific chemical formula or its salts, along with a pharmaceutical composition aimed at treating conditions such as lung cancer. By prioritizing the well-being of patients, Oncobix seeks to provide new therapeutic options that can significantly impact the treatment landscape for challenging medical conditions.

Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Pin Therapeutics is a biotechnology company developing therapeutic products that target disease-causing proteins for immune diseases, cancer, and aging-related conditions. It employs protein degradation systems to break down these proteins.

Hutom is a surgical service platform that leverages digital innovation to enhance the diagnosis and management of surgical procedures. The company specializes in robotics and laparoscopic surgery, offering an interactive platform that includes analytical diagnosis tailored to individual patient needs. Hutom's technology encompasses surgical video processing, recognition, analysis, and predictive capabilities, allowing for a simulated examination of surgeries. Additionally, it provides 3D anatomical images and AI-based surgical analysis reports, which aid medical professionals in efficiently managing patient complications and improving surgical methods. Through its comprehensive data platform, Hutom aims to positively impact the quality of surgical care.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Otus is a healthcare institute that specializes in advanced eyecare system.

Kandesai is a personalized tumor immunotherapy developer, focusing on the development of immunotherapy platforms based on tumor neoantigens. It has independently developed 3 tumor drug pipelines based on neoantigens and innovative pipelines for liver cirrhosis with independent intellectual property rights. Help patients suppress tumor recurrence and metastasis.

I-Sense is the development and manufacturing of bio-related sensors and analyzers.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.

Eyevensys S.A.S. is a Paris-based company that specializes in non-viral gene therapy for ophthalmology. Founded in 2008, it focuses on developing innovative solutions to improve drug delivery methods for ocular diseases. The company utilizes its proprietary Electro-Transfection (ET) technology to administer plasmids to the ciliary muscle, allowing for the sustained release of therapeutic proteins directly into the vitreous, addressing conditions such as uveitis, age-related macular degeneration, and various retinopathies, including central retinal vein occlusion and diabetic retinopathy. Eyevensys aims to overcome the limitations of current treatment options, which often involve invasive procedures like intravitreal injections and surgeries. By enhancing compliance, ocular bioavailability, and tolerability, Eyevensys seeks to create a robust product pipeline that delivers improved clinical outcomes while minimizing the need for frequent and invasive interventions.

S-Alpha Therapeutics Inc. is a digital therapeutics company based in Seoul, South Korea, established in 2019. It specializes in researching and developing health applications and platform technologies that leverage digital devices for the treatment of various diseases. The company’s product pipeline includes SAT-001, an application focused on ophthalmology for eye disease treatment; SAT-002, which addresses neurological conditions; SAT-003, designed for oncology to support cancer patients in their recovery; and SAT-008, aimed at public crises to address social issues. In addition to its health applications, S-Alpha Therapeutics also develops therapeutic devices, striving to provide innovative solutions for unmet medical needs across multiple therapeutic areas, including ophthalmology, neuropsychiatry, and cancer.

SK Plasma Co., Ltd. is a South Korean company specializing in the production of plasma-derived products aimed at treating various medical conditions, including hypoalbuminemia, hemorrhagic shock, antithrombin deficiency, and tetanus. Established in 2015 and based in Seongnam-si, the company focuses on developing high-quality plasma derivatives that serve as essential medicines for conditions such as congenital immunodeficiency diseases and hemophilia. SK Plasma has gained a strong reputation in the export market, reflecting its commitment to enhancing human health and ensuring safety through its innovative products. As a subsidiary of SK Chemicals Co., Ltd., SK Plasma leverages its parent company's expertise while concentrating on its core competencies in plasma derivatives to provide effective solutions for healthcare professionals and patients alike.

Cell in Cells is a biotechnology company focused on advancing regenerative medicine through its innovative cell therapy products. Utilizing advanced 3D technology, the company researches and develops novel biopharmaceuticals and cell therapies aimed at improving human health. By harnessing the potential of stem cells, Cell in Cells strives to create effective therapeutic solutions that enable medical professionals to treat a variety of diseases. The company's commitment to innovation positions it at the forefront of regenerative medicine, contributing significantly to the development of treatments designed to restore health and enhance patient outcomes.

Maxvax Health is a biotechnology company focused on the development and commercialization of innovative vaccines. The company specializes in vaccine technology targeting viral diseases, including rotavirus, shingles, and herpes. By advancing these vaccines, Maxvax Health aims to enhance treatment options for healthcare professionals and improve patient outcomes. Through its efforts in vaccine development, the company seeks to address significant health challenges posed by viral infections.

TSD Life Sciences Co., Ltd., established in 2016 and based in Seoul, South Korea, specializes in the research and development of pharmaceuticals targeting rare and intractable diseases, with a primary focus on cancer. The company offers comprehensive clinical research services, including non-clinical studies, clinical trials, orphan drug designation, and project management, aiming to develop innovative antibody drugs for treating previously incurable conditions.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

Innogen Pharmaceutical Technology is an international biopharmaceutical company specializing in the development and manufacturing of innovative drugs. The company utilizes advanced genetic engineering and recombinant protein biopharmaceutical processes to create new therapies. Its primary focus is on addressing the treatment needs of patients suffering from diabetic metabolic diseases and significant central nervous system disorders. Through its research and development efforts, Innogen aims to deliver effective solutions that enhance patient care and improve health outcomes.

Founded in 2016, Geneos Therapeutics specializes in developing personalized cancer immunotherapies targeting neoantigens. Its proprietary platform enables the creation of tailored treatments based on individual patients' tumor mutations.

Hutom is a surgical service platform that leverages digital innovation to enhance the diagnosis and management of surgical procedures. The company specializes in robotics and laparoscopic surgery, offering an interactive platform that includes analytical diagnosis tailored to individual patient needs. Hutom's technology encompasses surgical video processing, recognition, analysis, and predictive capabilities, allowing for a simulated examination of surgeries. Additionally, it provides 3D anatomical images and AI-based surgical analysis reports, which aid medical professionals in efficiently managing patient complications and improving surgical methods. Through its comprehensive data platform, Hutom aims to positively impact the quality of surgical care.

Founded in 2007, MicuRx Pharmaceuticals discovers and develops novel antibiotics to combat drug-resistant bacterial infections. Its pipeline includes MRX-I, an oral antibiotic for gram-positive infections, MRX-IV for intravenous use, MRX-V for gram-negative bacteria, and MRX-VIII, a polymyxin for gram-negative infections. The company operates under a hybrid U.S./China business model.

Founded in 2016, Humanscape specializes in blockchain-based health data platforms. It collects comprehensive patient health data, including genotype, clinical, and phenotype information, to facilitate drug discovery and improve treatments for intractable and rare diseases.

DoctorHere is a smart medical clinic using AI and IT to provide primary care both in-person and virtually

EvidNet is a healthcare IT company focused on providing Real World Evidence (RWE) solutions that leverage hospital data to enhance research and decision-making in the life sciences and healthcare sectors. The company collaborates with over 50 university and tertiary hospitals in Korea to generate Real World Data (RWD) using the OMOP-CDM standard. Its FeederNet® data platform facilitates multi-institutional research and allows for AI-driven federated machine learning, ensuring privacy and security are maintained. EvidNet's platform is designed to support precision and predictive medicine by creating an interoperable, real-time healthcare data network. This network offers tailored statistical analysis to meet the specific needs of hospitals and healthcare providers, enabling easier access to vital health information for both professionals and patients.

Virogin Biotech Ltd., founded in 2015 and based in Vancouver, Canada, specializes in the development of oncolytic virus therapeutics aimed at treating cancer. The company utilizes its innovative Synerlytic™ technical platform to enhance cancer treatment through novel immunotherapy approaches. Virogin's technology focuses on leveraging immunological principles to stimulate anticancer and antitumor immunity. By harnessing a robust and transient antiviral immune response, the company aims to improve systemic antitumor immunity via synergistic interactions with multiple therapeutic payloads. Virogin is dedicated to advancing its position as a leader in the field of immuno-oncology.

Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.

Mepsgen is a biotechnology research organization that focuses on pharmaceutical services and drug development.

Geninus is a biotechnology company specializing in clinical genome analysis solutions tailored for precision medicine clinics. By leveraging advanced genomic technologies, Geninus aims to enhance the accuracy and effectiveness of personalized medical treatments. The company focuses on delivering innovative tools and insights that facilitate the interpretation of genetic data, ultimately supporting healthcare providers in making informed decisions for patient care. Through its services, Geninus contributes to the evolving landscape of precision medicine, promoting better health outcomes through individualized approaches to treatment.

G2GBIO specializes in biotechnology, focusing on the development and supply of sustained-release pharmaceuticals using its proprietary microsphere technology (InnoLAMP). The company aims to improve patient outcomes globally by extending drug half-life and enhancing delivery systems.

eBrace is a company focused on the research, development, and production of digital 3D printing technology specifically tailored for orthodontics. The firm specializes in creating innovative solutions for dental applications, including bracketless invisible appliances, customized lingual invisible appliances, and dentures. By leveraging advanced 3D printing techniques, eBrace aims to deliver precise and detailed dental products that meet the needs of both practitioners and patients.

Haoxinqing is an online medical service platform that specializes in mental psychology and chronic disease management. The company offers remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to enhance patient experience and improve health outcomes, making it easier for individuals to manage their mental health and chronic conditions effectively.

Actym Therapeutics is a biotechnology company based in Berkeley, California. Founded in 2017, the company specializes in the discovery and development of novel immuno-oncology therapies to treat cancer. Actym's proprietary platform, STACT, uses attenuated bacteria to deliver multiplexed immunomodulatory payloads directly to tumor-resident immune cells, targeting intractable pathways with minimal systemic toxicities.

Immunobiome is a biotechnology company focused on developing microbiome-based therapeutics aimed at treating challenging diseases, including cancer, autoimmune disorders, allergies, and neurological conditions. By leveraging advanced immunology, bioinformatics, and fundamental microbiome research, the company seeks to create innovative solutions that address conditions often deemed incurable. Its platform specializes in targeted treatments that can help manage intractable immune-related diseases and improve patient outcomes in various health challenges, including organ transplant rejections and inflammation-related issues.

Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.

Founded in 2016, Humanscape specializes in blockchain-based health data platforms. It collects comprehensive patient health data, including genotype, clinical, and phenotype information, to facilitate drug discovery and improve treatments for intractable and rare diseases.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies and vaccines for infectious diseases and cancer. The company leverages a proprietary platform built around modified simian adenoviral vectors (ChAdOx1, ChAdOx2) and a Modified Vaccinia Ankara boost vector to stimulate potent CD8+ T cell responses, aiming to create durable immune protection. Its pipeline spans clinical and preclinical programs targeting solid tumors, viral infections, and prophylactic vaccines, with an emphasis on T-cell–oriented approaches that guide the immune system to address chronic infections, autoimmunity, and cancer.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.

G2GBIO specializes in biotechnology, focusing on the development and supply of sustained-release pharmaceuticals using its proprietary microsphere technology (InnoLAMP). The company aims to improve patient outcomes globally by extending drug half-life and enhancing delivery systems.

Hisense Bio offers treatment for intractable dental diseases. They provide research on original technology for tooth development and dentin regeneration. They developed physiological dentin regeneration technology and periodontal ligament regeneration technology based on basic dental research . They offer treatment of intractable dental diseases such as tooth decay, dental hypersensitivity, tooth decay, dental caries, and periodontal disease.

KBP is a leading biotechnology company focused on developing innovative therapies for unmet medical needs in areas such as cardiovascular, respiratory, inflammatory, and autoimmune diseases. It leverages a proprietary compound library and expertise in organ-specific disease models to deliver advanced therapeutic innovations.

Genome & Company, headquartered in Seongnam, South Korea, specializes in researching microbes and probiotics to develop dietary supplements, cosmeceuticals, and novel drugs targeting conditions such as obesity, diabetes, acne, atopic dermatitis, and cancer-related therapies.

Otus is a healthcare institute that specializes in advanced eyecare system.

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company headquartered in Nes Ziona, Israel, focused on developing allogeneic drugs aimed at rebalancing the immune system. The company's lead product, Allocetra, is an immunotherapy candidate currently undergoing multiple clinical trials. These include a Phase IIb trial for severe sepsis, an investigator-initiated Phase II trial for COVID-19 patients in severe and critical conditions, and a Phase IIa trial for preventing Graft Versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, Enlivex is exploring Allocetra's potential in preventing complications from bone marrow transplants and acute multiple organ failure. The company also aims to develop cell-based therapies that enhance the efficacy of treatments for solid tumors through immune checkpoint rebalancing. Founded in 2005 by Professor Dror Mevorach, Enlivex utilizes a novel approach that focuses on inducing immune tolerance by employing apoptotic cells to modulate inflammatory and autoimmune responses.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Shanghai Henlius Biotech, Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the research, development, production, and commercialization of biologics, particularly monoclonal antibody (mAb) biosimilars and novel therapies. Founded in 2010, the company focuses on oncology and autoimmune diseases, offering products such as HLX01, a biosimilar for treating non-Hodgkin lymphoma. Henlius is actively advancing its pipeline, with multiple products under review for regulatory approval, alongside conducting numerous clinical studies for various therapies. The company collaborates with partners, including agreements to develop treatments for COVID-19 and eye diseases. Shanghai Henlius Biotech is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, established in 2009, and operates out of the Shanghai Caohejing High-Technology Park.

Elastagen is a clinical-stage medical company focused on developing products based on human protein tropoelastin, a vital component for tissues that require elasticity, such as skin and blood vessels. The company has created a synthetic version of elastin that mirrors the natural protein found in the human body, allowing for innovative applications in skin rejuvenation, scar remodeling, and tissue repair. Elastagen's offerings include injectable synthetic human elastin and chemically cross-linked tropoelastin for aesthetic purposes, aimed at helping patients maintain skin elasticity and suppleness. Founded through the acquisition of intellectual property from research conducted by Prof Weiss at the University of Sydney, Elastagen has attracted significant investment from both Australian and international life science venture capital groups. Its operations have grown from Australia to include production facilities in Europe and clinical activities in the UK.

KAHR medical is a biopharmaceutical company developing fusion protein drugs for cancer and autoimmune disease treatment. Founded in 2005, it specializes in immuno-oncology, focusing on T-cell mediated tumor destruction and targeting CD47 tumors.

BioPharmX Corporation is a specialty pharmaceutical company focused on developing innovative treatments for dermatologic conditions through its proprietary HyantX topical delivery system. The company’s clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase IIb trials for treating inflammatory lesions of acne, and BPX04, which is in Phase IIb studies for papulopustular rosacea. BioPharmX aims to address unmet medical needs in large and underserved markets, particularly within dermatology, women's health, and Ear, Nose, and Throat (ENT) therapy. The company leverages its patented drug delivery technologies to create novel prescription products and is supported by a team with extensive experience in pharmaceutical development, regulatory compliance, and intellectual property. Based in Campbell, California, BioPharmX serves a range of clients, including pharmaceutical companies, healthcare providers, and dermatologists.

EuBiologics Co., Ltd., established in 2010 and based in Seoul, South Korea, is a biopharmaceutical company specializing in the development and supply of vaccines for epidemic prevention and antibiotic resistance. Its product portfolio includes Euvchol, an oral cholera prevention vaccine, and CRM197, a diphtheria toxin mutant vaccine. The company also offers customized services for mammalian and microbial cell-derived biopharmaceuticals, supporting clients from cell line development to GMP production, along with regulatory support. Additionally, EuBiologics provides contract testing services, process and formulation development, and licensing consulting services, contributing to human health across various stages of life.